GoAI
Get started
Sunwels Co.,Ltd. logo

Sunwels Co.,Ltd.

9229.T

JPXHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

¥118

+¥4.00 · +3.51%

Aug 24, 2:42 PM JST

9229.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Sunwels Co., Ltd. primarily delivers nursing care services, with its operations prominently featuring the "PD house" model. The company runs specialized residential facilities for seniors diagnosed with Parkinson's disease and also manages a Kaatsu training gym. Its extensive service portfolio encompasses daily care, in-home assistance, customized care planning, and home modification services. Additionally, Sunwels oversees various medical-specific establishments. Established in 2006, the company is headquartered in Kanazawa, Japan.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
JP
CEO
Ryotatsu Nawashiro
Listed since
Jun 27, 2022
Employees
3,570

Market position

Day range

Current ¥118

52-week range

Current ¥118

Open
¥113
Previous close
¥114
Volume
391.4K
1.07× average
Average volume
366.06K
Average daily volume
Market cap
3.83B JPY
Beta
-0.03
Market reference 1
50-day average
¥132.38
-10.86% below average
200-day average
¥257.48
-54.17% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
33.03B JPY
P/E (TTM)
-2.57×
P/B (TTM)
0.6×
P/S (TTM)
0.13×
EV / EBITDA
17.54×
Earnings yield
-20.67%
Free cash flow yield
-18.74%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
9.50%
Operating margin
-3.69%
Net margin
-5.16%
Return on equity
-23.75%
Return on assets
-3.63%
Return on invested capital
-3.02%

Financial health

Debt / equity
4.52×
Current ratio
1.33×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends29%16%4%-9%Gross margin, FY2021: 19.58%Gross margin, FY2022: 24.47%Gross margin, FY2023: 25.51%Gross margin, FY2024: 18.47%Gross margin, FY2025: 9.82%Operating margin, FY2021: 3.00%Operating margin, FY2022: 7.21%Operating margin, FY2023: 11.31%Operating margin, FY2024: 4.21%Operating margin, FY2025: -4.35%Net margin, FY2021: 0.13%Net margin, FY2022: 2.29%Net margin, FY2023: 3.99%Net margin, FY2024: -3.49%Net margin, FY2025: -5.89%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 19.58%. Gross margin FY2022 24.47%. Gross margin FY2023 25.51%. Gross margin FY2024 18.47%. Gross margin FY2025 9.82%. Operating margin FY2021 3.00%. Operating margin FY2022 7.21%. Operating margin FY2023 11.31%. Operating margin FY2024 4.21%. Operating margin FY2025 -4.35%. Net margin FY2021 0.13%. Net margin FY2022 2.29%. Net margin FY2023 3.99%. Net margin FY2024 -3.49%. Net margin FY2025 -5.89%.

Income trends

Revenue

28.14B JPY+6.19%

Operating income

−1.22B JPY−2.34B JPY

Net income

−1.66B JPY-79.03%
Income trends across reported periods31.12B JPY19.2B JPY7.28B JPY−4.64B JPYRevenue, FY2021: 8.17B JPYRevenue, FY2022: 13.24B JPYRevenue, FY2023: 20.11B JPYRevenue, FY2024: 26.5B JPYRevenue, FY2025: 28.14B JPYOperating income, FY2021: 245.57M JPYOperating income, FY2022: 953.91M JPYOperating income, FY2023: 2.27B JPYOperating income, FY2024: 1.12B JPYOperating income, FY2025: −1.22B JPYNet income, FY2021: 10.65M JPYNet income, FY2022: 303.6M JPYNet income, FY2023: 802M JPYNet income, FY2024: −925M JPYNet income, FY2025: −1.66B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 8.17B JPY. Revenue FY2022 13.24B JPY. Revenue FY2023 20.11B JPY. Revenue FY2024 26.5B JPY. Revenue FY2025 28.14B JPY. Operating income FY2021 245.57M JPY. Operating income FY2022 953.91M JPY. Operating income FY2023 2.27B JPY. Operating income FY2024 1.12B JPY. Operating income FY2025 −1.22B JPY. Net income FY2021 10.65M JPY. Net income FY2022 303.6M JPY. Net income FY2023 802M JPY. Net income FY2024 −925M JPY. Net income FY2025 −1.66B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue28.14B JPY26.5B JPY20.11B JPY13.24B JPY8.17B JPY
Cost of goods sold25.37B JPY21.6B JPY14.98B JPY10B JPY6.57B JPY
Gross profit2.76B JPY4.89B JPY5.13B JPY3.24B JPY1.6B JPY
Research and development—59M JPY21M JPY20.15M JPY23.08M JPY
Selling, general, and administrative3.99B JPY3.22B JPY2.55B JPY2.02B JPY1.16B JPY
Operating expenses3.99B JPY3.78B JPY2.86B JPY2.29B JPY1.35B JPY
Interest income8M JPY3M JPY—347K JPY251K JPY
Interest expense1.2B JPY814M JPY635M JPY372.26M JPY160.76M JPY
Depreciation and amortization1.86B JPY1.38B JPY816M JPY493.16M JPY311.92M JPY
Operating income−1.22B JPY1.12B JPY2.27B JPY953.91M JPY245.57M JPY
Net income−1.66B JPY−925M JPY802M JPY303.6M JPY10.65M JPY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 2 misses, 0 met estimates
Average EPS surprise
-119.20%
2 comparable reports
Latest EPS result
-17.17

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates99.5454.8710.2-34.47Q1 '25MissQ1 '25No estimateQ2 '25MissQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26No estimateQ3 '26No estimate
Q1 2025, reported Feb 12, 2025: actual -9.44, estimate 90.3, surprise -110.45%, Miss. Q1 2025, reported Feb 19, 2025: actual -11.66, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual -25.23, estimate 90.3, surprise -127.94%, Miss. Q3 2025, reported Aug 12, 2025: actual -22.35, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual -24.42, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -16.6, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual 12.3, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual -17.17, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.94B7.26B6.58B5.9BQ1 '25MissQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26No estimate
Q1 2025, reported Feb 12, 2025: actual 6.45B JPY, estimate 7.16B JPY, surprise -9.95%, Miss. Q1 2025, reported Feb 19, 2025: actual 7.21B JPY, estimate 7.63B JPY, surprise -5.59%, Miss. Q2 2025, reported May 15, 2025: actual 6.2B JPY, estimate 6.51B JPY, surprise -4.72%, Miss. Q3 2025, reported Aug 12, 2025: actual 6.61B JPY, estimate 6.94B JPY, surprise -4.79%, Miss. Q4 2025, reported Nov 14, 2025: actual 6.8B JPY, estimate 7.2B JPY, surprise -5.50%, Miss. Q1 2026, reported Feb 13, 2026: actual 7.33B JPY, estimate 7.46B JPY, surprise -1.84%, Miss. Q2 2026, reported May 12, 2026: actual 7.4B JPY, estimate 7.43B JPY, surprise -0.38%, Miss. Q3 2026, reported Aug 12, 2026: actual 7.3B JPY, estimate —, surprise —, Comparison unavailable.

9229.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,989

-0.31%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,817

+0.92%

HOYA Corporation logo

7741.T

HOYA Corporation

¥25,030

+0.54%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,280

+0.70%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,866.5

+1.16%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,405

+0.75%

ETFs holding 9229.T

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core TOPIX ETF logoiShares Core TOPIX ETF1475.T
Market value
2.07M
Weight
0.00%
AUM
2.89T JPY
Expense ratio
0.05%
Price / 1D
¥418.2+0.05%
Avantis International Small Cap Value ETF logoAvantis International Small Cap Value ETFAVDV
Market value
11.8K
Weight
—
AUM
20.24B USD
Expense ratio
0.36%
Price / 1D
$111.95+1.06%
Avantis International Equity ETF logoAvantis International Equity ETFAVDE
Market value
4.32K
Weight
—
AUM
19.1B USD
Expense ratio
0.23%
Price / 1D
$94.26+0.87%
Avantis International Small Cap Equity ETF logoAvantis International Small Cap Equity ETFAVDS
Market value
1.01K
Weight
—
AUM
340.61M USD
Expense ratio
0.30%
Price / 1D
$80.49+0.93%

Continue in GoAI

Research 9229.T

research.disclaimer